secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-01-30T23:59:59+00:00
Accession:  0000950170-24-008530
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum's oral sulopenem meets Phase 3 uUTI endpoint, shows superiority over Augmentin
--------------------------------------------------------------------------------

- Primary endpoint met: overall success 61.7% (sulopenem) vs 55.0% (Augmentin); 95% CI lower bound >0 showing statistical superiority.
- No serious adverse events on sulopenem; discontinuations <1% in both arms; safety consistent with prior trials.
- NDA resubmission planned for Q2 2024; FDA action expected in Q4 2024 if deficiencies addressed.
- Company initiating strategic process to sell, license, or dispose of sulopenem rights to maximize value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024008530/0000950170-24-008530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024008530/itrm-20240130.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-008530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer